KR102141039B1 - Compositions for preventing or treating Psoriasis comprising extract of Rumex acetosella - Google Patents

Abstract

The present invention relates to a composition for the prevention or treatment of psoriasis comprising the extract of Arabidopsis. Specifically, the present invention relates to a pharmaceutical composition for preventing or treating psoriasis, a composition for external application for skin, a cosmetic composition, and a quasi-drug composition comprising the extract of Aegiswim. The composition comprising the baby swimming extract provided in the present invention reduces the activity of IL6 and Stat3 signals involved in psoriasis induction, inhibits cell proliferation of keratinocytes and relieves psoriasis lesions when applied to lesions of animal models of psoriasis It can be used as a composition for preventing or treating psoriasis.

Description

Composition for preventing or treating psoriasis comprising extract of Aegiswim {Compositions for preventing or treating Psoriasis comprising extract of Rumex acetosella}

The present invention relates to a composition for the prevention or treatment of psoriasis comprising the extract of Arabidopsis. Specifically, the present invention relates to a pharmaceutical composition for preventing or treating psoriasis, a composition for external application for skin, a cosmetic composition, and a quasi-drug composition comprising the extract of Aegiswim.

Psoriasis is a chronic inflammatory skin disease in which rashes forming red papules or plaques of various sizes and covered with silver-white scales occur repeatedly on the skin of the whole body. About 3% of the world's population is psoriasis patients and 2% of the total population in Korea. Psoriasis is histologically characterized by abnormal differentiation of the stratum corneum, and its cause is not clearly known, and genetic and immunological studies are continuing. However, there is still only a method to temporarily eliminate the lesions of psoriasis, and there is no treatment to completely prevent recurrence, so the demand for treatment for psoriasis continues to increase.

The most widely used steroid as a traditional skin disease treatment causes side effects such as diabetes and hypertension, and has become a social problem due to its abuse, and recently developed immunomodulators act only on specific targeted areas to safely immunize Antibody preparations that were expected to cause inhibitory action have been reported to cause unexpected and serious side effects such as immune disorders, infections, and cancer, and many studies are needed for effective psoriasis treatment (Paul, Carle F., et al. , Journal of Investigative Dermatology 120.2 (2003): 211-216.).

Meanwhile, baby swimming ( Rumex acetosella ) is a perennial plant of the Polygonaceae family, and its origin is Europe, but it is naturally distributed throughout Korea and around the world. The rhizome grows as it grows to the side, the stem stands upright, 20-50cm high, has hair-like protrusions, has a vertical vertical line, has a purple color, and has a sour taste with leaves. The leaves from the roots are agglomerated, the petioles are long, spear-shaped, pointed, and the ears-like protrusions spread from side to side. The leaves on the stem are misaligned and have the same shape as the leaves from the root, but are small in size. The flowers are male and female, bloom in reddish green in May-June, and run in a conical shape at the end of the stem. The male flower is 3mm in diameter and has 6 calyx pieces and 6 stamens each. The female flower is smaller than the male flower, has 6 calyx pieces, 1 pistil, and 3 pistils and finely divided pistil heads. Light stems and leaves are used for edible use, and in Chinese medicine, stems and leaves are used as medicinal products, such as dissipative mothers, which have anti-cancer effects and have an effect on the digestive system. However, the effects of pity psoriasis on baby swimming are not known.

Under such a background, the present inventors tried to develop a method for improving and treating psoriasis using natural extracts that are more stable than synthetic drugs. As a result, it was confirmed that the Aegiswim extract shows the effect of treating psoriasis, and the present invention Was completed.

One object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of psoriasis, including extracts of Aegiswim.

Another object of the present invention is to provide a composition for external application for skin for preventing or improving psoriasis comprising a baby swimming extract.

Another object of the present invention is to provide a cosmetic composition for the prevention or improvement of psoriasis, including a baby swimming extract.

Another object of the present invention is to provide a quasi-psoriasis prevention or improvement quasi-drug composition comprising a baby swimming extract.

Another object of the present invention is to provide a method for preventing or treating psoriasis comprising the step of administering a baby swimming extract to an individual other than a human.

As one aspect for solving the above problems, the present invention provides a pharmaceutical composition for the prevention or treatment of psoriasis, including the extract of Arabidopsis.

Hereinafter, a composition for preventing or treating psoriasis, including the baby swimming extract in the present invention will be described in detail.

The term in the present invention, "Baby swimming ( Rumex acetosella )” is a perennial plant of the Polygonaceae family, and its origin is Europe, but it is naturally distributed throughout Korea and around the world. The rhizome grows as it grows to the side, the stem stands upright, 20-50cm high, has hair-like protrusions, has a vertical vertical line, has a purple color, and has a sour taste with leaves. The leaves from the roots are agglomerated, the petioles are long, spear-shaped, pointed, and the ears-like protrusions spread from side to side. The leaves on the stem are misaligned and have the same shape as the leaves from the root, but are small in size. The flowers are male and female, bloom in reddish green in May-June, and run in a conical shape at the end of the stem. The male flower is 3mm in diameter and has 6 calyx pieces and 6 stamens each. The female flower is smaller than the male flower, has 6 calyx pieces, 1 pistil, and 3 pistils and finely divided pistil heads. Light stems and leaves are used for edible use, and in Chinese medicine, stems and leaves are used as medicinal products, such as dissipative mothers, which have anti-cancer effects and have an effect on the digestive system.

The term "Psoriasis" in the present invention is a chronic inflammatory skin disease in which red papules or rashes of various sized red papules or plaques are repeatedly formed on the skin of the whole body, covered with silver-white scales, and tissues. It is characterized by hyperplasia of the epidermis and inflammation of the dermis, which occurs at a frequency of 1 to 2% of the population. It has been found that psoriasis increases the activity of T cells, the immune cells in the skin, and as a result, secreted immune substances stimulate the skin's keratinocytes, causing excessive proliferation and inflammation of keratinocytes. Because the skin cells grow rapidly, dandruff-like keratin appears on the skin. In addition, genetic factors, environmental factors, drugs, skin irritation, dryness, upper respiratory tract inflammation, and mental stress have been proven to cause or worsen psoriasis.

In the present invention, it was first identified that the Arabidopsis extract has an effect of preventing or treating psoriasis.

Prevention or treatment of psoriasis of the present invention may be achieved through suppressing cell proliferation of keratinocytes.

Cell proliferation of the keratinocytes may be stimulated by an immune substance, and the immune substance may be a cytokine, specifically, IL6.

It is known that the IL6 is involved in the immune response of the skin and causes an inflammatory reaction by external stimulation. In addition, the inflammatory response is also associated with the activity of Stat3, a protein related to skin wound healing, and skin cells are proliferated more than necessary due to the skin cell proliferation due to the skin wound healing effect due to the overactivity of Stat3. It is known that this occurs and psoriasis is induced.

The prevention or treatment of psoriasis of the present invention may be achieved through a decrease in the activity of IL6, and the reduction of the activity of IL6 may be achieved through a decrease in the activity of Stat3.

In one embodiment of the present invention, after treating the Arabidopsis extract with keratinocytes that increased cytokine expression by treating M5, the level of IL6 was confirmed, and it was confirmed that IL6 decreased compared to the control group (FIG. 3).

In addition, in another embodiment of the present invention, as a result of analyzing the activity of Stat3 after treating the Arabidopsis extract on keratinocytes having increased cytokine expression by treating M5, Stat3 (pStat3) activated in the control group treated with M5 While increased, it was confirmed that pStat3 decreased in the baby swimming treatment group (FIG. 4 ).

The term "extract" in the present invention refers to a material obtained by extracting a substance, specifically, the extract obtained by the extraction treatment of the baby swimming of the present invention, the diluent or the concentrate of the extract, or the extract The dried product obtained by drying, the extract or the like, or a mixture or a mixture thereof, includes extracts of the extract itself and all formulations that can be formed using the extract.

The method for extracting the baby swimming is not particularly limited, and can be extracted according to a method commonly used in the art.

The extract of the baby swimming may be extracted from the root, stem, leaf, flower, or fruit of the baby swimming, and is not particularly limited thereto.

The baby water extract includes, but is not limited to, those extracted with a solvent selected from the group consisting of water, lower alcohols having 1 to 4 carbon atoms and mixed solvents thereof.

The term "prevention" in the present invention refers to all actions of suppressing or delaying the symptoms of dry eye syndrome by administration of a composition comprising the baby swimming extract according to the present invention.

The term "treatment" in the present invention refers to all actions in which symptoms of the dry eye syndrome are improved or beneficially changed by administration of a composition containing the baby swimming extract according to the present invention.

The term "pharmaceutical composition" in the present invention means that it is manufactured for the purpose of preventing or treating a disease, and can be used by being formulated in various forms according to each conventional method. For example, powders, granules, tablets, capsules, suspensions, emulsions, syrups, etc. may be formulated into a formulation, and may be used in the form of external preparations, suppositories, and sterile injectable solutions. Specifically, it may be used in a form suitable for application to the skin, for example, formulated in a cream, ointment, gel or lotion.

The composition of the present invention may be prepared in the form of a pharmaceutical composition for the prevention or treatment of psoriasis, which further comprises a suitable carrier, excipient or diluent commonly used in the manufacture of a pharmaceutical composition. non-naturally occuring carriers.

In the present invention, carriers, excipients and diluents that may be included in the pharmaceutical composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, Calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.

In the case of formulation, it is prepared using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents and surfactants. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc. These solid preparations include at least one excipient in the upper leaf extract and its fractions, for example, starch, calcium carbonate , Sucrose (lactose), gelatin, etc. are prepared by mixing. In addition, lubricants such as magnesium stearate and talc are used in addition to simple excipients. Liquid preparations for oral use may include various excipients, such as wetting agents, humectants, sweeteners, fragrances, and preservatives, in addition to water and liquid paraffin, which are simple diluents commonly used for suspending agents, intravenous solutions, emulsions, syrups, etc. have. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, and suppositories. Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. As a base for suppositories, witepsol, macrogol, tween 61, cacao butter, laurin butter, and glycerogelatin may be used.

The dosage of the pharmaceutical composition of the present invention can be determined by a person skilled in the art in consideration of the purpose of use, the degree of poisoning of the disease, the age, weight, sex, history of the patient, or the type of substance used as an active ingredient. For example, the pharmaceutical composition of the present invention may be administered at about 0.1 ng to about 1,000 mg/kg per adult, specifically 1 ng to about 1,000 mg/kg, and the frequency of administration of the composition of the present invention is particularly limited. However, it can be administered once a day or divided into doses and administered several times. The above dosage does not limit the scope of the invention in any aspect.

The pharmaceutical composition of the present invention may include, but is not limited to, 1 to 500 μg/ml, specifically 5 to 400 μg/ml, and more specifically 10 to 250 μg/ml, of the Arabidopsis extract.

In another aspect, the present invention provides a composition for external application for skin for preventing or improving psoriasis comprising a baby swimming extract.

The terms "baby swimming", "extract", and "psoriasis" in the present invention are as described above.

The composition for external application for skin according to the present invention may be formulated by containing a cosmetic or dermatologically acceptable medium or base. These are all formulations suitable for topical application, for example solutions, gels, solids, dough anhydrous products, emulsions, suspensions, microemulsions, microcapsules, microgranules or ionic forms (liposomes) obtained by dispersing an oil phase in an aqueous phase, and It can be provided in the form of a non-ionic vesicle dispersant, or in the form of a cream, skin, lotion, powder, ointment, spray, pack or conceal stick. It can also be used in the form of a foam or in the form of an aerosol composition further containing a compressed propellant. These compositions can be prepared according to conventional methods in the art.

In addition, the composition for external application for skin according to the present invention is a fatty substance, an organic solvent, a solubilizer, a thickening agent, a gelling agent, a softening agent, an antioxidant, a suspending agent, a stabilizing agent, a foaming agent, a fragrance, a surfactant, water, and an ionic type Or nonionic emulsifiers, fillers, metal ion blockers, chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic actives, lipid vesicles or any other commonly used in cosmetics. It may contain auxiliaries commonly used in cosmetic or dermatological fields such as ingredients. The adjuvant is introduced in an amount generally used in the cosmetic or dermatological field.

In yet another aspect, the present invention provides a cosmetic composition for preventing or improving psoriasis comprising the Arabidopsis extract.

The terms "baby swimming", "extract", and "psoriasis" in the present invention are as described above.

In the present invention, the cosmetic composition is a solution, ointment for external use, cream, foam, nutrition lotion, soft lotion, pack, softened water, emulsion, makeup base, essence, soap, liquid detergent, bathing agent, sunscreen cream, sun oil, Suspensions, emulsions, pastes, gels, lotions, powders, soaps, surfactant-containing cleansing, oils, powder foundations, emulsion foundations, wax foundations, patches and sprays can be prepared in the formulation selected from the group consisting of, but may It is not limited.

The cosmetic composition of the present invention may further include one or more cosmetically acceptable carriers formulated in general skin cosmetics, for example, oil, water, surfactant, moisturizer, lower alcohol, thickener as a common ingredient , Chelating agents, pigments, preservatives, fragrances, etc. may be appropriately blended, but is not limited thereto.

The cosmetically acceptable carrier included in the cosmetic composition of the present invention may vary depending on the formulation of the cosmetic composition.

When the formulation of the present invention is an ointment, paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide, etc. as carrier components This may be used, but is not limited thereto. These may be used alone or in combination of two or more.

When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder, etc. may be used as a carrier component, and in the case of a spray, additionally, chlorofluorohard Propellants such as locarbon, propane/butane or dimethyl ether, but are not limited thereto. These may be used alone or in combination of two or more.

When the formulation of the present invention is a solution or emulsion, a solvent, solubilizer or emulsifier may be used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, Propylene glycol, 1,3-butyl glycol oil, and the like can be used, and in particular, cottonseed oil, peanut oil, corn seed oil, olive oil, castor oil and sesame oil, glycerol aliphatic esters, polyethylene glycol or fatty acid esters of sorbitan May be used, but is not limited thereto. These may be used alone or in combination of two or more.

When the formulation of the present invention is a suspension, liquid diluents such as water, ethanol or propylene glycol as carrier components, suspensions such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, micro Crystalline cellulose, aluminum metahydroxide, bentonite, agar or trakant may be used, but is not limited thereto. These may be used alone or in combination of two or more.

When the formulation of the present invention is a surfactant-containing cleansing, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivatives, methyltaurate, sarcosinate, fatty acid amide as a carrier component Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, linoline derivatives or ethoxylated glycerol fatty acid esters may be used, but are not limited thereto. These may be used alone or in combination of two or more.

In the cosmetic composition of the present invention, in addition to the above essential components, other components that are usually blended into a cosmetic may be blended as necessary. Specifically, as a blending component that may be added, fats and oils, moisturizers, emollients, surfactants, organic and inorganic pigments, organic powders, ultraviolet absorbers, preservatives, fungicides, antioxidants, plant extracts, pH adjusters, alcohols, pigments, Flavoring agents, blood circulation accelerators, cooling agents, limiting agents, purified water, and the like.

In yet another aspect, the present invention provides a quasi-psoriasis quasi-drug composition for preventing or improving psoriasis comprising the extract.

The terms "baby swimming", "extract", and "psoriasis" in the present invention are as described above.

The term "quasi-drug" in the present invention refers to articles that are less effective than medicines among articles used for the purpose of diagnosing, treating, improving, alleviating, treating or preventing diseases of humans or animals. For example, quasi-drug products under the Pharmaceutical Affairs Law exclude products used for pharmaceutical use, and include products used for the treatment or prevention of disease in humans/animals, products that have little or no direct action on the human body.

Specifically, the quasi-drug may include an external preparation for skin and personal hygiene products. More specifically, it may be a disinfecting cleaner, shower foam, gagreen, wipes, detergent soap, hand wash, or ointment, but is not limited thereto.

When the composition according to the present invention is used as a quasi-drug additive, the composition may be added as it is or used with other quasi-drugs or quasi-drug components, and may be suitably used according to a conventional method. The mixing amount of the active ingredient can be appropriately determined according to the purpose of use.

In another aspect, the present invention provides a method for preventing or treating psoriasis comprising the step of administering a baby swimming extract to an individual other than a human.

The term "individual" in the present invention may refer to all animals including humans who have had or are likely to develop psoriasis. The animal may be a mammal, such as a cow, a horse, a sheep, a pig, a goat, a camel, an antelope, a dog, a cat, etc., which need treatment for similar symptoms, but are not limited thereto.

Specifically, the method for preventing or treating the present invention may include the step of administering the composition in a pharmaceutically effective amount to an individual who has or is at risk of developing psoriasis.

The term "administration" in the present invention means the introduction of the pharmaceutical composition of the present invention to a patient in any suitable way, and the route of administration of the composition of the present invention can be varied by oral or parenteral as long as it can reach the target tissue. It can be administered via route.

The composition comprising the baby swimming extract provided in the present invention reduces the activity of IL6 and Stat3 signals involved in psoriasis induction, inhibits cell proliferation of keratinocytes and relieves psoriasis lesions when applied to lesions of animal models of psoriasis It can be used as a composition for preventing or treating psoriasis.

1 is a graph analyzing the cytotoxicity of the Arabidopsis extract; CTL, control; DMSO, Voice Control.
Figure 2 is a graph showing the effect of inhibiting cell proliferation of Arabella swimming extract on keratinocytes.
Figure 3 is a graph analyzing the activity of psoriasis-related cytokines according to the Aegiswim extract treatment; M5, M5 (IL22, IL1a, TNF-α, Oncostatin M, IL17A) treatment group.
4 is a view analyzing the activity of Stat3 according to the treatment of Aegiswim extract; vehicle, Eumseong Control.
5 is a diagram showing an experimental design schematic for an animal model of psoriasis.
6 is a view analyzing the change in psoriasis lesions according to the application of the cream containing the baby swimming extract from the back of the animal model of psoriasis; IMQ, imiquimod; CLO, Clobetasol (Dermobate).
7 is a view analyzing the change in psoriasis lesions according to the application of the cream containing the baby swimming extract from the ear of the animal model of psoriasis.
8 is a graph showing the efficacy of improving psoriasis of Aegiswim extract with PASI score.

Hereinafter, the present invention will be described in more detail through examples. However, these examples are intended to illustrate the present invention, and the scope of the present invention is not limited to these examples.

Example 1. Preparation of Aegi Swimming Extract

In the present invention, the Arabidopsis extract was purchased and used as an extract extracted with 99.9% methyl alcohol from the Korea Plant Extract Bank, and dissolved in DMSO.

Experimental Example 1.Efficacy evaluation of Arabidopsis extract in keratinocytes

Experimental Example 1-1. Cytotoxicity analysis of Arabidopsis extract

To confirm the cytotoxicity of the baby swimming extract, after adding 10% (v/v) fetal bovine serum (FBS, Gibco) and antibiotic (Antibiotic antimycotic) to DMEM (Dulbecco's modified Eagle Medium) 37 HaCaT cell line, a human-derived skin keratinocyte, was cultured in a 5% CO ₂ incubator. When the cells grew to about 80% of a 100 mm culture dish, the cells were lightly washed with PBS for detachment, treated with trypsin-EDTA (Gibco/BRL), left at 37° C. for 8 minutes, and then the cells were collected. Passage culture was performed once every 2-3 days.

After incubation, cytotoxicity analysis was confirmed by WST 1 assay. Dispense in a 96-well plate at a concentration of 3×10 ⁴ cell/ml, maintain 37°C, 5% CO ₂ in the incubator, pre-incubate for 24 hours, and treat the baby swimming extract at a concentration of 25 to 800 μg/ml to 24 Incubated for hours. Thereafter, a water-soluble tetrazolium salt (WST-1) was treated and incubated for 1 hour so that WST-1 is reduced by enzymatic action of viable cells. Then, it was measured at 450 nm using a microplate reader.

As a result, as shown in FIG. 1, it was shown that the cell viability of about 15% was decreased at 200 ug/ml, and no cytotoxicity was observed at a concentration below that.

Experimental Example 1-2. Confirmation of the effect of inhibiting the proliferation of keratinocytes in Aegi-Soo extract

As one of the typical symptoms of psoriasis, abnormal proliferation of keratinocytes is known. In this regard, in order to confirm the effect of the Arabidopsis extract on keratinocyte proliferation rate, the proliferation rate of keratinocytes was confirmed using a WST 1 assay at a concentration at which no cytotoxicity was observed. Specifically, skin keratinocytes HaCaT was dispensed into a 96-well plate at a concentration of 3×10 ⁴ cells/ml, pre-incubated for 24 hours while maintaining 37° C., 5% CO ₂ in a incubator, and the concentration of 20 to 160 ug/ml. The extract was treated with Arabidopsis extract and cultured for 48 and 72 hours. Thereafter, WST-1 was treated to incubate 1 hour so that WST-1 is reduced by enzymatic action of viable cells. Then, it was measured at 450 nm using a microplate reader.

As a result, as shown in FIG. 2, after 48 hours of culture, it was shown that cell proliferation of about 20% was suppressed at a concentration of 160 ug/ml, and after 72 hours of culture, at a concentration of 80 to 160 ug/ml, 20 to 30% It was confirmed that cell proliferation was suppressed.

Accordingly, it was possible to confirm the possibility of treating psoriasis by suppressing keratinocyte proliferation of the Arabidopsis extract.

Experimental Example 1-3. Confirmation of M5 induced cytokine reduction effect of Arabidopsis extract

The cytokine IL6 is known to cause psoriasis through an inflammatory reaction. In this regard, in order to confirm the effect of the baby swimming extract on the cytokine, HaCaT cells were treated with M5 (IL22, IL1a, TNF-α, Oncostatin M, IL17A; J Immunol 2010, 184:5263-5270) to cytosine. After increasing the expression of Cain, the level of IL6 was analyzed by treating the Arabidopsis extract (20ug/ml or 80ug/ml).

As a result, as shown in FIG. 3, it was confirmed that cytokines increased when M5 was treated, and that IL6 was significantly decreased when the baby water extract was treated after M5 treatment.

Accordingly, it was possible to confirm the possibility of treating psoriasis through IL6 reduction of the Arabidopsis extract.

Experimental Example 1-4. Extract of Baby Swim Stat3 Confirm the inhibitory effect

In the results of Experimental Examples 1-3, it was confirmed that the level of inflammatory cytokines is increased by M5, and the activity of pStat3 is known as a major cause affecting the level of inflammatory cytokines. That is, it is known that when Stat3 is phosphorylated and activated, the level of inflammatory cytokines is thereby increased. Accordingly, the purpose of this invention was to determine whether the extract of Aegiswim can affect the activity of Stat3.

HaCaT cells were dispensed at a 5×10 ⁵ cell/well in a 60 mm culture dish and cultured for 24 hours. After that, the M5 and/or each candidate natural product extract was treated for each concentration, incubated for 4 hours, washed with PBS, and then extracted with protein using a lysis buffer. Kept in. For the protein quantification used in this experiment, a BCA assay was used, 30 μg of protein was loaded onto a 10% SDS-PAGE gel, and electrophoresis was performed for 100 V for 2 hours, and then transferred to a nitrocellulose blotting membrane. . After stopping the reaction with 5% skim milk for one hour, pSTAT3 and Stat3 antibodies were reacted at 4° C. for 18 hours, washed 10 times with TBS-T solution (TBS containing 0.2% Tween 20), and washed 3 times for 2 hours. The antibody anti-rabbit IgG HRP linked antibody was reacted at room temperature for 1 hour, washed 3 times for 10 minutes with TBS-T solution, and protein expression was measured using an ECL kit.

As shown in FIG. 4, it was confirmed that the activity of pStat3 in HaCaT cells was significantly increased by M5 treatment, and significantly decreased by treatment with Arabidopsis extract.

Accordingly, it could be predicted that the Arabidopsis extract would have an effect on IL6 or Stat3-related inflammatory diseases such as psoriasis.

Experimental Example 2. Evaluation of Efficacy of Baby Swim Extract in Animal Model

Experimental Example 2-1. psoriasis Efficacy verification of baby swimming extract on skin such as animal models

In order to verify the efficacy of psoriasis treatment of Aegiswim extract in vivo, an animal model inducing psoriasis by applying imiquimod (IMQ) to mouse skin was used. The imiquimod used in the test was Aldara cream (5% imiquimod, 3M Health Care Ltd. UK), and the control group was Dermovate (clobetasol 17-propionate 0.5 mg/1 g, Glaxo Operation, UK). Was used.

By epilating the back and ears of the mouse and applying the test substance, the thickness and erythema of the back and ears were measured on the 0th, 2nd, 4th, and 6th days, respectively, and the thickness of the skin was used with the Digimatic Thickness Gage (Mitutoyo, Japan), and the erythema was Dermacatch. The numerical values were measured using ⓡ (Colorix, Swiss). Aldara Cream was applied to the epilated back and ear areas of 7 week old Balb/c mice at 62.5 mg/day for 7 days to induce psoriasis-like skin.

Aegiswim extract was made into an ointment form and applied to the skin, and the composition is as follows. To a total of 5g formulation, add white petrolatum: 4521.6mg, sorbitan sesquioleate: 23.86mg, propylene glycol: 204.50mg, baby swimming extract (5%):250mg (extract dissolved in 0.5% DMSO) and bath in 50℃ And mixed. Ointments used in the negative control were prepared including white petrolatum, sorbitan sesquioleate, and propylene glycol. The ointment formulation of Aegisuyoung extract was applied to the back and ears of 80mg 5 hours after applying IMQ for 6 days. 5 is a schematic diagram of the experimental process.

After extracting the skin tissues of each group prepared above, 10% formalin was used to fix them for 24 hours, and then, a paraffin block was produced through a water-dehydration treatment to make micro-slices of 4 um thickness and attached to slide glasses. The prepared slides were stained with hematoxylin and eosin (H & E) to observe the degree of damage to the skin tissues by observing it with an optical microscope and quantitatively analyze the thickness of the epidermis.

As a result, as shown in FIG. 6, the group applied with IMQ was able to confirm that psoriasis was induced due to a marked increase in erythema and keratin compared to the vehicle group, whereas the group treated with Arabidopsis extract after IMQ application was applied to the IMQ group It was confirmed that the thickness of the contrast erythema and stratum corneum decreased.

Accordingly, it could be predicted that the extract of Arabidopsis was effective for psoriasis disease in the direction of reducing the thickness of the erythema and stratum corneum.

Experimental Example 2-2. psoriasis Verification of the effect of baby swimming extract on the skin of animal model ears

The experiment was conducted in the ear of the mouse in the same manner as in Experimental Example 2-1.

As a result, as shown in FIG. 7, it was confirmed that the group applied with IMQ significantly increased the erythema, keratin and ear thickness compared to the vehicle group. On the contrary, it was confirmed that the group treated with the Arabidopsis extract after IMQ application significantly decreased the erythema and keratin thickness compared to the IMQ application group.

Accordingly, it was confirmed that the Aegiswim extract relieves psoriasis-related symptoms, and thus it can be predicted that it is effective for psoriasis disease.

Experimental Example 2-3. PASI Through score psoriasis Improvement efficacy evaluation

In order to evaluate the efficacy of improving the psoriasis of Aegiswim extract, the severity of psoriasis lesions, such as skin thickness, erythema, and scales are scored according to the PASI index (http://pasi.corti.li, ver 1.7.1) It was evaluated as 4 points.

As a result, as shown in FIG. 8A, it was confirmed that the thickness of the back skin was reduced in the group treated with the baby swimming extract compared to the IMQ group. In addition, as shown in 8d, the PASI graph of the scores of the thickness of the back skin, erythema, and scales showed that the PASI score was decreased in the Arabidopsis extract treated group compared to the IMQ group, indicating that the psoriasis lesion severity was improved.

Taken together, the efficacy of the Arabidopsis extract in vitro and in an animal experimental model for the hyperplasia and inflammatory response of keratinocytes, one of the main symptoms of psoriasis, was evaluated. As a result, the cell proliferation rate of keratinocytes by the Arabidopsis extract in HaCaT cells The effect of psoriasis treatment could be predicted by suppressing proliferation of keratinocytes, and the possibility of inhibition of inflammatory response-mediated psoriasis was confirmed by confirming that phosphorylation of IL6 and Stat3 was significantly reduced. In addition, in the animal model of psoriasis induced by IMQ, it was confirmed that the degree of erythema, thickness, and keratin of the skin was reduced by the extract of Aegiswim, which directly suppressed psoriasis-related symptoms. Therefore, it is determined that the improvement and treatment efficiency for psoriasis can be significantly increased by using the present invention.

From the above description, those skilled in the art to which the present invention pertains will appreciate that the present invention may be implemented in other specific forms without changing its technical spirit or essential features. In this regard, the embodiments described above should be understood as illustrative in all respects and not restrictive. The scope of the present invention should be construed as including all changes or modifications derived from the meaning and scope of the following claims rather than the above detailed description and equivalent concepts thereof.

Claims (8)

As a pharmaceutical composition for the prevention or treatment of psoriasis comprising the extract of Arabidopsis, the prevention or treatment of psoriasis is achieved through inhibition of cell proliferation of keratinocytes, pharmaceutical composition.
delete According to claim 1,
The prevention or treatment of psoriasis is achieved by reducing the activity of IL6 or Stat3, pharmaceutical composition.
According to claim 1,
The composition is a pharmaceutical composition comprising a baby swimming extract 10 to 250μg / ml.
A composition for external application for skin for preventing or improving psoriasis comprising an extract of Aegiswim, wherein the prevention or improvement for psoriasis is achieved through suppressing cell proliferation of keratinocytes, a composition for external application for skin.
As a cosmetic composition for preventing or improving psoriasis comprising the extract of Arabidopsis, the prevention or improvement of psoriasis is achieved through suppressing cell proliferation of keratinocytes, cosmetic composition.
As a quasi-psoriasis quasi-drug composition comprising the Arabidopsis extract, the psoriasis prevention or improvement is achieved through suppressing cell proliferation of keratinocytes, quasi-drug composition.
A method for preventing or treating psoriasis comprising administering a baby swimming extract to an individual other than a human, wherein the prevention or treatment of psoriasis is achieved through suppressing cell proliferation of keratinocytes.

Images